Genmab: Leader in the European healthcare sector impresses with study data and fresh all-time high!

Genmab has been a frequent topic of discussion since early August, as the healthcare company focused on the development of antibodies announced a strong half-year report along with a revision of its forecast. In particular, the multiple myeloma medication Darzalex serves as a stable source of revenue. Building on this, Genmab can further advance its independent marketing in the oncology sector. The success of this strategic endeavor is evidenced by the antibody Petosemtamab. The data presented on October 28 shows more than just a clinical success...